Neuropathic pain and hemp: a Cochrane review without clear evidence of relief

What do studies say about hemp in neuropathic pain?

There is no clear evidence that hemp alleviates neuropathic pain by at least half. This is the conclusion of the Cochrane review update published in January 2026 (PMID:41548880), which included 21 randomized, double-blind studies and 2187 participants treated for two to twenty-six weeks.

The review updates work from 2018 and categorizes the studied preparations into three families: those dominated by tetrahydrocannabinol, balanced, and those dominated by cannabidiol. In the first family, the risk difference for relief of at least half was 0.14, with a 95 percent confidence interval ranging from minus 0.07 to 0.37, calculated from seven studies and 534 participants. The interval includes zero, so this result does not distinguish the preparation from placebo, and the authors assessed the certainty of the evidence as very low.

The balanced family performed similarly. There is no clear evidence of relief of at least half for it, although these preparations increased the percentage of individuals rating their improvement as significant by 0.07. The authors themselves noted that this effect is not clinically significant. For preparations dominated by cannabidiol, no clear evidence was found either. Three families, three times the same conclusion.

The measure on which this conclusion stands is the percentage of patients experiencing a reduction in pain by half compared to baseline. In pain studies, it is treated as a threshold for noticeable improvement in daily functioning, rather than a number convenient to calculate.

What is the difference between statistically significant and clinically significant results?

The former refers to the probability of a chance occurrence, while the latter refers to the magnitude of change perceived by the patient. An effect can be statistically certain and yet so small that the patient does not notice it. On this page, the distinction is not a digression, as it precisely delineates the boundary between the three cited works.

The three studies measured three different magnitudes, and all three turned out to be small. The Cochrane review reported a 0.07 increase in the percentage of individuals rating their improvement as significant for balanced preparations, after which it itself labeled it clinically insignificant. The review update published in Annals of Internal Medicine (PMID:41429020) measured a decrease in pain intensity of 0.78 points on a scale from zero to ten for oral preparations dominated by tetrahydrocannabinol and 0.54 points for extracts administered to the oral mucosa.

The work published in PLOS ONE (PMID:36716312) shows where the threshold lies. The measured decrease in chronic pain was 0.43 points on the numerical scale, and the confidence interval ranged from minus 0.72 to minus 0.15, so the result is statistically certain. However, the authors added that it does not reach the magnitude they previously accepted as minimally important, and 59 out of the 65 included studies and every calculated result were burdened with a high risk of systematic error.

The distinction has practical implications. A statistically significant result only indicates that the measured difference is unlikely to have arisen from random variation. It does not indicate whether a patient with diabetic polyneuropathy will notice a change in walking, sleeping, or working. With a difference of half a point on a ten-point scale, the answer to the latter question is usually negative.

What strain characteristics are important here?

None, as far as we are asking about these studies. The three cited reviews grouped preparations according to the ratio of both main compounds, origin, and route of administration, rather than by cultivar name. Neither the terpene profile nor the strain name was a variable that anyone analyzed or reported.

The authors of the review published in Annals of Internal Medicine themselves listed the lack of product description among the limitations of their work. They knew the ratio of tetrahydrocannabinol to cannabidiol and whether the preparation was synthetic, purified, or extracted, but they had no data on the plant from which the raw material originated. From such material, it is impossible to calculate whether one strain performs better than another.

The Polish pharmacy describes the raw material differently than these studies. The prescription states the Latin name of the raw material and the declared content of both compounds, while the trade name of the strain is the manufacturer's label, not a pharmacopoeial parameter. Terpenes such as myrcene or caryophyllene are sometimes mentioned in commercial descriptions, but in none of the three discussed studies was their contribution to analgesic action counted. Separate texts from this cluster gather what has been shown for individual terpenes, and czego nie. Dowody dla spasticity. Multiple sclerosis is described on a separate page, as it is the only neurological indication in which preparations with a defined composition have been studied. The compilation of strains available in Polish pharmacies leads to a separate review.

What does the doctor decide, and what does the patient decide?

The doctor decides everything related to treatment: the indication, the preparation, the dosage, and the route of administration. The patient decides whether to undertake such treatment at all and reports to the doctor what they feel. Dried flower is a pharmaceutical raw material issued exclusively on a prescription marked with the symbol Rpw.

A prescription for dried flower is a prescription for a medicine prepared in a pharmacy and is subject to separate regulations. It indicates the name of the raw material in Latin and the declared content of both compounds, and the term for its realization is 30 days from the date of issuance, as directly stipulated by pharmaceutical law. It cannot be issued with a deferred realization date. The pharmacy prepares the medicine according to what the doctor has written and has no right to substitute one strain for another.

This arrangement also indicates what this site does not do. Pharmaceutical law prohibits advertising medicines issued by a doctor's prescription to the public, which is why we only describe the state of evidence here and do not suggest any preparation or strain. The choice belongs to the attending physician, who knows the entire list of medications taken by the patient and their diagnosis. The formal path is described in a separate entry on obtaining a prescription in Poland.

How long does the effect last after vaporization, and how long after ingestion?

Shorter after vaporization, significantly longer after ingestion. The difference is important when reading the cited studies, as they primarily measured oral preparations and extracts administered to the mucous membrane of the oral cavity, not inhaled raw material. The route of administration changes the course of action more than the choice of a specific strain of dried flower.

The route of administration determines the course more than the variety itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two hours, and the episode can last six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks nothing is happening after thirty minutes and takes another dose will receive both doses at once. The above ranges describe the route of administration, not this variety; pharmacokinetic studies for a single cultivar have not been published.

The translation to the cited results is direct. Since a decrease in pain intensity of 0.78 points was measured for swallowed forms, and 0.54 points for aerosol on the mucous membrane, both numbers describe the course specific to those routes, not inhalation. Transferring such a result to vaporized raw material would require a study that is not present in this trio.

What side effects have been reported with the use of cannabis for this indication?

Primarily from the nervous system. In the Cochrane review, preparations with a predominance of tetrahydrocannabinol may have increased such events, with a risk difference of 0.25 within a range of 0.14 to 0.37. The benefit for this indication remained uncertain, and this particular harm was measured and described with a specific number.

The number comes from a Cochrane review covering 21 randomized studies with a double-blind trial, totaling 2187 participants, with observation lasting from two to twenty-six weeks. A systematic review from the Annals of Internal Medicine, based on 25 short-term studies with placebo and 2303 participants, in which neuropathic pain constituted 64 percent of cases, described a clear increase in dizziness, drowsiness, and nausea in both groups of preparations with a higher content of tetrahydrocannabinol.

The third paper, a review with meta-analysis and sequential analysis based on 65 studies with 7017 participants, recorded the same trend: an increase in mild adverse events, without a detectable increase in severe events. The comparison thus comes out asymmetrical. On the side of benefits are results that the authors themselves do not consider important for the patient, while on the side of harms are quantifiable results.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

What cannot be read from these studies?

That is, how hemp works over the years, and how a single strain of dried flower performs. The longest of the studies included in the Cochrane review lasted twenty-six weeks, and the review from the Annals of Internal Medicine covered only short-term studies, from one month to half a year. This trio of papers says nothing about long-term treatment.

The authors of the Cochrane review rated the certainty of evidence for most results as very low, and those effects that achieved statistical significance were described by them as clinically insignificant. In none of the three groups of preparations was it shown that hemp provided relief more often than placebo by at least half, which is the measure that pain researchers consider significant for the patient. The studies included medications with known dosages, not pharmacy-grade dried flower described by strain name.

There are also no comparisons between the preparations themselves. All three papers compare hemp with placebo, not one form of raw material with another, so they do not answer the question of which performs better. An honest summary thus sounds different from how it is often summarized in headlines: the evidence is weak and uncertain. A negative result in such a review means a lack of clear evidence, not evidence of absence.

Frequently asked questions about hemp and neuropathic pain

Do hemp products treat neuropathic pain?

There is no clear evidence that they provide relief of at least half. The Cochrane review from January 2026 found no such evidence in any of the three families of preparations, and rated the certainty of evidence for most results as very low.

What does a statistically significant but clinically insignificant result mean?

It means that the measured difference likely did not arise by chance, but is too small for the patient to notice. This is how the authors of the Cochrane review described an increase of 0.07 in the percentage of people rating their own improvement as significant.

Does any strain of dried flower perform better for neuropathic pain?

This cannot be read from these studies. Preparations were grouped according to the ratio of both compounds and the route of administration, not by cultivar name, and the lack of product description was noted by the authors of one of the papers as a limitation.

What adverse effects were described in these studies?

Most commonly dizziness, drowsiness, and nausea. Preparations with a predominance of tetrahydrocannabinol may increase adverse events from the nervous system, with a risk difference of 0.25 in a review covering 21 studies.

Is dried flower available without a prescription?

No. Dried flower is a pharmaceutical raw material issued exclusively on a prescription marked with the symbol Rpw, and the medication is prepared by the pharmacy. The fulfillment period for such a prescription is 30 days from the date of issuance.

Do the results of these studies pertain to vaporization?

Only indirectly. The cited reviews primarily measured oral preparations and extracts administered to the mucous membrane of the oral cavity, so they describe the course specific to these routes of administration, not the inhalation of the raw material.

The material is informational in nature and does not replace medical advice. Hemp is a pharmaceutical raw material issued by a doctor's prescription in the Rpw category, and treatment decisions are made by the attending physician. The editorial text was prepared by redakcja ubucha.pl.